Retrophin to Present at the BMO 2020 Prescriptions for Success Healthcare Conference
Retrophin, Inc. (NASDAQ: RTRX) announced that CEO Eric Dube will present at the BMO 2020 Prescriptions for Success Healthcare Conference on June 23, 2020, at 10:00 a.m. ET.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
Retrophin, Inc. (NASDAQ: RTRX) announced that CEO Eric Dube will present at the BMO 2020 Prescriptions for Success Healthcare Conference on June 23, 2020, at 10:00 a.m. ET. A live webcast will be available, with an archived replay accessible for 30 days afterward. Retrophin specializes in developing therapies for rare diseases, with its pipeline featuring sparsentan, which is in late-stage development for focal segmental glomerulosclerosis (FSGS) and IgA nephropathy (IgAN). The company also collaborates on additional rare disease research and supports its R&D through revenue from existing commercial products.
Details
News Market Reaction – RTRX
The recorded move for RTRX in the trading session of this news was +1.22%.
Data tracked by StockTitan Argus. Session date unavailable.
AI-generated analysis. How Rhea-AI works. Not financial advice.
SAN DIEGO, June 19, 2020 (GLOBE NEWSWIRE) -- Retrophin, Inc. (NASDAQ: RTRX) today announced that Eric Dube, Ph.D., chief executive officer, will present at the BMO 2020 Prescriptions for Success Healthcare Conference on Tuesday, June 23, 2020 at 10:00 a.m. ET.
A live webcast of the presentation will be available at http://ir.retrophin.com/events and an archived replay will be accessible for up to 30 days.
About Retrophin
Retrophin is a biopharmaceutical company specializing in identifying, developing and delivering life-changing therapies to people living with rare disease. The Company’s approach centers on its pipeline featuring sparsentan, a product candidate in late-stage development for focal segmental glomerulosclerosis (FSGS) and IgA nephropathy (IgAN), rare disorders characterized by progressive scarring of the kidney often leading to end-stage renal disease. Research in additional rare diseases is also underway, including partnerships with leaders in patient advocacy and government research to identify potential therapeutics for NGLY1 deficiency and Alagille syndrome, conditions with no approved treatment options. Retrophin’s R&D efforts are supported by revenues from the Company’s commercial products Chenodal®, Cholbam®, Thiola® and Thiola EC®.
Retrophin.com
Contact:
Chris Cline, CFA
Senior Vice President, Investor Relations & Corporate Communications
888-969-7879
IR@retrophin.com
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.